Advances in parallel artificial membrane permeability assay and its applications

Yaoxue Xuebao

Volumn 46, Issue 8, 2011, Pages 890-895

  Wu, Yi Fan ^a   Liu, Hui ^a   Ni, Jing Man ^a  

^a LANZHOU UNIVERSITY   (China)

Author keywords

Parallel artificial membrane permeability assay; Passive diffusion; Phospholipid

Indexed keywords

BLOOD BRAIN BARRIER; DRUG PENETRATION; DRUG RESEARCH; DRUG SCREENING; GASTROINTESTINAL ABSORPTION; HIGH THROUGHPUT SCREENING; LIPID MEMBRANE; MEMBRANE PERMEABILITY; PARALLEL ARTIFICIAL MEMBRANE PERMEABILITY ASSAY; REPRODUCIBILITY; REVIEW; SKIN PENETRATION;

ABSORPTION; ANIMALS; BLOOD-BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; HUMANS; INTESTINAL ABSORPTION; MEMBRANES, ARTIFICIAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SKIN ABSORPTION; STOMACH;

EID: 80053503644     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. Masia N. Focus on: Intellectual Property Rights [M]. Washington: US Department of State, 2006: 82-83.
2. Wexler DS, Gao LP, Anderson F, et al. Linking solubility and permeability assays for maximum throughput and reproducibility [J]. J Biomol Screen, 2005, 10: 383.
3. Hampton SL, Kinnaird AI. Genetic interventions in mammalian cells; applications and uses in high-throughput screening and drug discovery [J]. Cell Biol Toxicol, 2010, 26: 43-55.
4. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes [J]. J Med Chem, 1998, 41: 1007-1010. (Pubitemid 28207375)
5. Thompson M, Lennox RB, Mcclelland RA. Structure and electrochemical properties of microfiltration filter-lipid membrane systems [J]. Anal Chem, 1982, 54: 76-81. (Pubitemid 12464206)
6. Chen XX, Murawski A, Patel K, et al. A novel design of artificial membrane for improving the PAMPA model [J]. Pharm Res, 2008, 25: 1511-1520.
7. Di L, Kerns E, Fan K, et al. High throughput artificial membrane permeability assay for blood-brain barrier [J]. Eur J Med Chem, 2003, 38: 223-232. (Pubitemid 36349665)
8. Liu H, Sabus C, Carter GT, et al. In vitro permeability of poorly aqueous soluble compounds using different solubilizers in the PAMPA assay with liquid chromatography/mass spectrometry detection [J]. Pharm Res, 2003, 20: 1820-1826. (Pubitemid 37449456)
9. Malakoutikhah M, Prades R, Teixido M, et al. N-Methyl phenylalaninerich peptides as highly versatile blood-brain barrier shuttles [J]. J Med Chem, 2010, 53: 2354-2363.
10. Kerns EH, Di L, Petusky S, et al. Combined application of parallel artificial membrane permeability assay and Caco-2 permeability assays in drug discovery [J]. J Pharm Sci, 2004, 93: 1440-1453. (Pubitemid 38725018)
11. Wohnsland F, Faller B. High-throughput permeability pH profile and high-throughput alkane/water logP with artificial membranes [J]. J Med Chem, 2001, 44: 923-930. (Pubitemid 32861617)
12. Avdeef A, Strafford M, Block E, et al. Drug absorption in vitro model: filter-immobilized artificial membranes. 2. Studies of the permeability properties of lactones in piper methysticum forst [J]. Eur J Pharm Sci, 2001, 14: 271-280. (Pubitemid 33001619)
13. Mensch J, Melis A, Mackie C, et al. Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability [J]. Eur J Pharm Biopharm, 2010, 74: 495-502.
14. Avdeef A, Tsinman O. PAMPA - a drug absorption in vitro model 13. Chemical selectivity due to membrane hydrogen bonding: in combo comparisons of HDM-, DOPC-, and DSPAMPA models [J]. Eur J Pharm Sci, 2006, 28: 43-50.
15. Avdeef A, Artursson P, Neuhoff P, et al. Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKaflux method [J]. Eur J Pharm Sci, 2005, 24: 333-349. (Pubitemid 40283516)
16. Nielsen PE, Avdeef A. PAMPA - a drug absorption in vitro model 8. Apparent filter porosity and the unstirred water layer [J]. Eur J Pharm Sci, 2004, 22: 33-41. (Pubitemid 38543012)
17. Lennernas H. Human intestinal permeability [J]. J Pharm Sci, 1998, 87: 403-410. (Pubitemid 28175799)
18. Liang WQ. Biopharmaceutics and Pharmacokinetics [M]. 3rd ed. Beijing: People's Medical Publishing House, 2007: 18-20.
19. Zhu CC, HE X. Methodology study of drug intestinal absorption [J]. Drug Eval Res, 2010, 33: 222-227.
20. Bendels S, Tsinman O, Wagner B, et al. PAMPA - excipient classification gradient map [J]. Pharm Res, 2006, 23: 2525-2535. (Pubitemid 44691599)
21. Avdeef A, Testa B. Physicochemical profiling in drug research: a brief state-of-the-art of experimental techniques [J]. Cell Mol Life Sci, 2002, 59: 1681-1689. (Pubitemid 35346972)
22. Sugano K, Nabuchi Y, Machida M, et al. Prediction of human intestinal permeability using artificial membrane permeability [J]. Int J Pharm, 2003, 257: 245-251. (Pubitemid 36507050)
23. Singh SP, Wahajuddin, Tewari D, et al. PAMPA permeability, plasma protein binding, blood partition, pharmacokinetics and metabolism of formononetin, a methoxylated isoflavone [J]. Food Chem Toxicol, 2011, 49: 1056-1062.
24. Klein T, Abgottspon D, Wittwer M, et al. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation [J]. J Med Chem, 2010, 53: 8627-8641.
25. Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood-brain barrier [J]. Neurobiol Dis, 2010, 37: 13-25.
26. Garberg P, Ball M, Borg N, et al. In vitro models for the blood-brain barrier [J]. Toxicol In Vitro, 2005, 19: 299-334. (Pubitemid 40248750)
27. Di L, Kerns EH, Bezar IF, et al. Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBB [J]. J Pharm Sci, 2009, 98: 1980-1991.
28. Tewes BJ, Galla HJ. Lipid polarity in brain capillary endothelial cells [J]. Endothelium, 2001, 8: 207-220. (Pubitemid 34056070)
29. Dagenais C, Avdeef A, Tsinman O, et al. P-glycoprotein deficient mouse in situ blood-brain barrier permeability and its prediction using an in combo PAMPA model [J]. Eur J Pharm Sci, 2009, 38: 121-137.
30. Liu Y, Zeng S. Advances in the MDCK-MDR1 cell model and its applications to screen drug permeability [J]. Acta Pharm Sin, 2008, 43: 559-564.
31. Tarrago T, Kichik N, Claasen B, et al. Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor [J]. Bioorg Med Chem, 2008, 16: 7516-7524.
32. Tsai PL, Tsai TH. Pharmacokinetics of baicalin in rats and its interactions with cyclosporin A, quinidine and SKF-525A: a microdialysis study [J]. Planta Med, 2004, 70: 1069-1074.
33. Cui FD. Pharmaceutics [M]. 6th ed. Beijing: People's Medical Publishing House, 2008: 466-468.
34. Wang CX, Liu YL. New development of transdermal drug delivery system [J]. Acta Pharm Sin, 2002, 37: 999-1002.
35. Ottaviani G, Martel S, Carrupt PA. Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability [J]. J Med Chem, 2006, 49: 3948-3954. (Pubitemid 43967892)
36. Sinko B, Kokosi J, Avdeef A, et al. A PAMPA study of the permeability-enhancing effect of new ceramide analogues [J]. Chem Biodivers, 2009, 6: 1867-1874.
37. Han M, Fu S, Fang XL, et al. Screening of panax notoginse-noside water in oil microemulsion formulations and their evaluation in vitro and in vivo [J]. Acta Pharm Sin, 2007, 42: 780-786.
38. Fujikawa M, Nakao K, Shimizu R, et al. The usefulness of an artificial membrane accumulation index for estimation of the bioconcentration factor of organophosphorus pesticides [J]. Chemosphere, 2009, 74: 751-757.